Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-21-060513

Options or other derivatives

  • Chief R&D Officer acquired 71,550 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2021-10-12 Grant or award : show line 1 in the form Stock Option +71,550 71,550 D
Loading xslF345X03/doc4.xml…